GlassScriptPhysician profile
Sheba Asghar
NPI 1780865758
$1,472.15
in general payments reported to CMS, 2019-2025
16 companies · $25.78 in 2025
The $25.78 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.57 · 2021: $153 · 2022: $192 · 2023: $508 · 2024: $575 · 2025: $25.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $583 · Travel and Lodging: $526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.05 |
| Travel and Lodging | $525.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $963.61 | 2021-2024 | Minimed 780g |
| Novo Nordisk INC | $64.13 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $57.17 | 2021 | |
| Philips North America LLC | $52.09 | 2023 | |
| Insulet Corporation | $45.74 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $38.03 | 2022-2023 | |
| Amgen INC. | $36.02 | 2022-2023 | Repatha |
| Embecta Corp. | $31.46 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Dexcom, INC. | $28.10 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.03 | 2022 | |
| Beta Bionics, INC. | $25.78 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Novartis Pharmaceuticals Corporation | $24.66 | 2022 | |
| Esperion Therapeutics, INC. | $24.03 | 2023 | Nexletol |
| Lilly USA, LLC | $18.84 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.57 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $15.89 | 2023 | Steglatro, Steglujan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheba Asghar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.